PMID: 6168508Oct 1, 1981Paper

Abnormalities of pancreatic somatostatin secretion corrected by in vivo insulin treatment of streptozotocin-diabetic rats

Diabetes
E R TrimbleA E Renold

Abstract

In islets removed from untreated streptozotocin-diabetic rats, the somatostatin-containing cells were unresponsive to changes in glucose concentration, while they did respond to raised cyclic AMP levels. By contrast, in vivo insulin treatment restored the glucose sensitivity of the somatostatin secreting cells. In addition, in vivo insulin treatment resulted in a lowering of the high basal somatostatin secretion rate found in islets from untreated diabetic rats. These changes were made without any alteration of islet insulin content or enhancement of the in vitro insulin secretion. These results indicate that there is not a basic defect in the glucoreceptor of the somatostatin cell in diabetes.

Citations

Jan 1, 1984·The Journal of Clinical Investigation·G J Taborsky, J W Ensinck
Sep 11, 1991·The Journal of Clinical Investigation·C J GreenbaumL J Klaff
Apr 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·O SegersG Somers
Feb 1, 1986·Clinics in Endocrinology and Metabolism·E SamolsG C Weir
Aug 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·G Williams, S R Bloom
Nov 29, 2016·Critical Reviews in Food Science and Nutrition·Giovanna MuscogiuriAnnamaria Colao
Aug 1, 1984·The American Journal of Physiology·M D Ruggere, Y C Patel

❮ Previous
Next ❯